Chiltern acquires Pacific Clinical Research
Expands operations and therapeutic depth in Asia-Pacific region
Chiltern has acquired Pacific Clinical Research, a pan-Asian contract research organisation (CRO) based in Singapore. Financial details have not been disclosed.
Building on its operations in India, Australia, Singapore and Taiwan, Chiltern has added new capabilities in Hong Kong, Korea, Malaysia, Philippines and Thailand.
The company said the move will enable it to offer integrated services throughout the Asia-Pacific region and in particular strengthen its oncology and anti-infective offerings.
Pacific Clinical Research founders Robert Teoh and Vonny Iskandar will join the Chiltern team as Managing Director, Asia-Pacific and Vice President, Asia-Pacific, respectively.
The acquisition comes just three months after Chiltern's purchase of Ockham, a specialist oncology and resourcing CRO, in July.
Chiltern CEO James Esinhart and COO Aize Smink said: 'We have worked with Robert Teoh for many years and our two organisations have always collaborated well. We have been looking for some time to strengthen Chiltern's direct presence in the Asia-Pacific region, so we jumped at the opportunity to acquire Pacific.'
Teoh added: 'Pacific Clinical Research has seen strong growth over four years and it was time for the business to integrate into a larger platform. I am excited to be leading Chiltern in the Asia-Pacific region and to be participating globally in specialised studies.'